Повик за аплицирање: “Lyfebulb-Novo Nordisk” самит и награда за иновации

Call-for-Applications-2017-Lyfebulb-Novo-Nordisk-Innovation-Summit-and-Award.png

Call for Applications: 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award

Call for Applications: 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award

 

The Lyfebulb-Novo Nordisk Innovation Summit will gather 10 patient entrepreneurs, who have founded start-ups, to pitch their ideas to venture capitalists, Novo Nordisk R&D leaders, researchers and engineers as well as the Lyfebulb founders, and engage in Q&A with the judging panel from around the world. The top three patient entrepreneurs will receive monetary awards, with the winner of the Lyfebulb-Novo Nordisk Innovation Award taking home 25,000 USD to further develop his or her idea.

“It is integral for the advancement in the care of diabetes to support young companies and new ideas,” says Karin Hehenberger, “as an organisation, Lyfebulb believes that the future of diabetes lies in the hands of the patient, which is why we are certain that the empowerment of patient entrepreneurs will ensure that innovative and effective ideas are brought to market,” she concluded.

All candidates are invited to submit applications to take part in the 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award on Lyfebulb’s website at http://lyfebulb.com/novo-nordisk-2017

Submissions will be accepted between 7 June 2017 and 15 September 2017, a review of which will be made shortly thereafter, and a selection of 10 finalists will be announced in the fall of 2017.

About Lyfebulb
Lyfebulb is a business focused on bridging patient communities with industry, and providing a strong voice to people living with chronic disease by empowering patient entrepreneurs.

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries.

Што мислиш ти?
  • Ви се допаѓа оваа вест? Препорачајте ја на Вашите пријателите преку следниве сервиси:
  • Mail